Navigation Links
Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
Date:10/17/2007

SOUTH SAN FRANCISCO, Calif., Oct. 17 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that its lead product candidate, picoplatin, has been granted orphan medicinal product designation for the treatment of small cell lung cancer (SCLC) by the European Commission. This designation is based on a recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA).

Picoplatin is currently being studied in the pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial in SCLC, which is evaluating overall survival as the primary endpoint and is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA.

"The receipt of orphan drug designation in the EU for picoplatin for the treatment of small cell lung cancer is an important achievement and builds on our success of obtaining orphan drug designation for picoplatin in the U.S.," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "Because many SCLC patients who are treated with platinum therapies relapse quickly or do not respond at all, new therapies that are active in this disease and that can overcome platinum resistance are urgently needed. We are committed to bringing picoplatin to market in the U.S. and the EU for this severely underserved patient population and are making significant progress in enrolling patients in our pivotal SPEAR trial for this indication."

About Orphan Drug Designation in the European Union

The EU orphan medicinal product designation aims to encourage the development of drugs involved in the diagnosis, prevention or treatment of a life-threatening or chr
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... September 04, 2015 , ... BioBots is ... 1, at the 2015 TERMIS World Congress in Boston. The launch comes following ... institutions around the world. The printer is revolutionary for its compact design, ease ...
(Date:9/3/2015)... , Sept. 3, 2015  Vermillion, Inc. (NASDAQ: ... gynecologic disease, today announced that Herbert Fritsche , ... ASPiRA LABS, is the recipient of the 2015 Abbott ... Biomarkers (ISOBM) for outstanding contributions to the field of ... award on October 5 th in Zakopane, ...
(Date:9/3/2015)... ... September 03, 2015 , ... Michigan-based technology startup ... early 2016. , The device, called the Halo H1, is a wearable ... sensing technology. These sensors track trending interstitial fluid levels in the body, in ...
(Date:9/2/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report "DNA Sequencing ... offering. This report briefly reviews basics ... and their applications. Current large and small sequencers ... Various applications of sequencing are described including those ...
Breaking Biology Technology:BioBots to Debut Desktop 3D Bioprinter for Living Tissue at TERMIS Global Tissue Engineering Conference in Boston 2BioBots to Debut Desktop 3D Bioprinter for Living Tissue at TERMIS Global Tissue Engineering Conference in Boston 3BioBots to Debut Desktop 3D Bioprinter for Living Tissue at TERMIS Global Tissue Engineering Conference in Boston 4Vermillion Announces Dr. Herbert Fritsche as Recipient of the 2015 Abbott Award from the International Society of Oncology and Biomarkers 2Technology Startup Halo Wearables to Unveil Non-Invasive Hydration Monitoring Device Early 2016 2Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2
... of the equation , ,Identity theft has seen the ... three years. The United States is faced with an ever-changing ... both sides of the equation, organizational and consumer. , ... to a new report from the Federal Trade Commission (FTC). ...
... pioneer company looks to reclaim lost ground , ,CHIPPEWA FALLS, ... operating out of offices on Lowater Road here in its hometown, ... wonderful heights. , ,With its next-generation X1, on the market since ... toward the future with a twinkle in its corporate eye that, ...
... often been regarded as the economic motor of the European ... of Scandinavia, to the east of the U.K. and France, ... the east European countries of Poland, the Czech Republic and ... not only one of Europes largest populations but considering ...
Cached Biology Technology:Are You Ready for Identity Theft? 2Are You Ready for Identity Theft? 3Are You Ready for Identity Theft? 4Are You Ready for Identity Theft? 5Are You Ready for Identity Theft? 6Are You Ready for Identity Theft? 7Cray Rides Again 2Cray Rides Again 3German Life Science Oktoberfest Comes to the Midwest 2German Life Science Oktoberfest Comes to the Midwest 3German Life Science Oktoberfest Comes to the Midwest 4German Life Science Oktoberfest Comes to the Midwest 5German Life Science Oktoberfest Comes to the Midwest 6
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:8/4/2015)... (NASDAQ: AMRI ) today reported financial and operating results for ... , Second quarter contract revenue of $ 85.2 ... Adjusted contract margins of 26 % , ... in EPS from royalties in the current quarter , ... are very pleased to present another strong financial quarter, with all ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... new molecular signature for a destructive and often lethal pediatric ... the hard-to-treat condition. In a study that included human ... in the November Journal of Clinical Investigation that ... process. Some patients have a second molecular conductor of disease ...
... A human monoclonal antibody developed by MassBiologics of ... patients with chronic hepatitis C virus (HCV) infection undergoing ... a week after transplant and delayed the time to ... 2 study were presented this week at The Liver ...
... Researchers studying the nature of crowds playing Foldit called ... of the methods already used by protein scientists., Gamers ... a protein central to research on AIDS. Today, ... of the National Academy of Sciences, University of ...
Cached Biology News:Possible treatment target found for main cause of severe liver disease in kids 2Possible treatment target found for main cause of severe liver disease in kids 3Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients 2Experimental drug suppresses rebound of hepatitis C virus in liver transplant patients 3Paper uncovers power of Foldit gamers' strategies 2Paper uncovers power of Foldit gamers' strategies 3
... clear advantages over traditional electrophoresis for ... mutation analysis, and size polymorphisms analysis. ... connectivity is ideal for basic research, ... The P/ACE Series automated capillary electrophoresis ...
... you reduce the chance of error. Thats ... Developed using Beckman Coulters extensive experience in ... technology, the CEQ 8000 is a fully ... fills the capillary array with a patented ...
The imaging screen-K (Kodak), is a 35 x 43 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The optional fixed lens, 105 mm, is for use with the VersaDoc imaging systems for imaging small samples at high resolution....
Biology Products: